Latent TB Testing Market: Current Analysis and Forecast (2024-2032)
Emphasis on Test Type (Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA)); Application (Household Contacts (HHC) of Tuberculosis (TB) Patients, People Living with HIV (PLHIV), Others); End User (Diagnostic Laboratories, Hospitals/clinics, Academic & Research Institutions); and Region/Country
Latent TB Testing Market Size & Forecast
The Latent TB Testing Market was valued at approximately USD 1.4 Billion in 2023 and is expected to grow at a substantial CAGR of around 7.8% during the forecast period (2024-2032) owing to rising tuberculosis (TB) incidence and increased need for screening in HIV/AIDS and transplant patients.
Latent TB Testing Market Analysis
Screening for Latent TB detects people with Mycobacterium tuberculosis infection who have no signs of active TB but are prone to develop the disease. Both TST and IGRAs are diagnostic tools used in the identification of TB infection in its latent form among populations at risk for TB transmission, such as healthcare workers, immunocompromised patients, and immigrants from TB-endemic countries.
To expand the market of latent TB testing, the companies work on creating more precise IGRA-based diagnostics. They are enhancing accessibility through collaborations with governments and NGOs, increasing investments in automation, focusing on point-of-care testing, and targeting high-burden regions at low costs. The use of digital platforms for integrated diagnostics is also increasing efficiency and market access.
For instance, on 24 April 2024, Revvity, Inc. (NYSE: RVTY) announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians, and ultimately patients, benefit from the resultant powerful solution. The T-SPOT.TB test detects latent tuberculosis infection (LTBI) and is an interferon-gamma release assay (IGRA) based on the enzyme-linked immunospot (ELISPOT) technology.
Latent TB Testing Market Trends
This section discusses the key market trends influencing the various segments of the Latent TB Testing market as identified by our research experts.
Interferon Gamma Released Assay (IGRA) Transforms Latent TB Testing Industry
The Interferon Gamma Released Assay (IGRA) due to its higher diagnostic accuracy, specificity, and capacity to differentiate between latent and active TB thus reducing the number of false positives results. It is implemented almost exclusively in high-income countries and among the populations in need of protection. Adding to this, IGRA is used by companies to provide new, more precise tests, such as QuantiFERON-TB and T-SPOT.TB, and to increase the efficiency of diagnostic process automation. They aim to cooperate with healthcare organizations to include IGRAs in regular check-ups and increase the availability of IGRAs via point of care. This technology has high relevance in the current and future healthcare systems since there is a great need for accurate diagnostic equipment.
On March 18, 2024, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
North America leads the market.
North America is the largest region for the growth of the latent TB testing market because of compulsory screening policies for immigrants, modern healthcare facilities, and the growing acceptance of TB prevention. The shifts towards accurate and convenient diagnostic tests, such as IGRAs, in the region also help to drive the market. They implement these tests by collaborating with healthcare systems, by automating these procedures, and through readily available digital alternatives that can easily be integrated into the routine check-ups offered by various organizations. Moreover, grants from governments as well as tuberculosis elimination initiatives make it popular among the targeted population.
For instance, on June 27, 2024, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that it welcomes new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QIAGEN’s market-leading QuantiFERON-TB Gold Plus (QFT-Plus).
Latent TB Testing Market Overview
The Latent TB Testing market is competitive, with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, and mergers and acquisitions. Some of the major players operating in the market are QIAGEN, Revvity, Abbott, BIOMÉRIEUX, Serum Institute of India Pvt. Ltd., Lionex GmbH, SD Biosensor, INC., Cepheid, Wantai BioPharm, AdvaCare Pharma.
Latent TB Testing Market News
On November 25, 2023, Revvity, a global company that leverages innovation in Diagnostics and Life Sciences announced the country launch of its T-SPOT.TB test for latent TB screening, at MICROCON in Lucknow.
On March 23, 2023, PerkinElmer’s Oxford Immunotec announced that the U.S. Food and Drug Administration (FDA) has approved the use of two additional cell isolation instruments with the Company’s previously approved T-Cell Select™ reagent kit, which is intended for in vitro diagnostic (IVD) use by certified laboratories with the T-SPOT®.TB test workflow.
In March 2022, PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021.
On November 29, 2021, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) announced that the U.S. Food and Drug Administration (FDA) has approved the LIAISON®QuantiFERON®-TB Gold Plus assay for use on DiaSorin’s automated LIAISON® XS platform.
On 24 March 2021, World Tuberculosis (TB) Day and bioMérieux, a world leader in the field of in vitro diagnostics, announced the CE marking of its innovative and fully-automated test VIDAS® TB IGRA (Interferon-Gamma Release Assay) to diagnose latent TB infection.
Latent TB Testing Market Report Coverage
Report Attribute | Details |
Base year | 2023 |
Forecast period | 2024-2032 |
Growth momentum | Accelerate at a CAGR of 7.8% |
Market size 2023 | USD 1.4 Billion |
Regional analysis | North America, Europe, Asia-Pacific, Rest of the World |
Major contributing region | Asia-Pacific is expected to grow at the highest CAGR during the forecasted period. |
Key countries covered | U.S., Canada, Germany, France, UK, Spain, Italy, China, Japan, and India |
Companies profiled | QIAGEN, Revvity, Abbott, BIOMÉRIEUX, Serum Institute of India Pvt. Ltd., Lionex GmbH, SD Biosensor, INC., Cepheid, Wantai BioPharm, AdvaCare Pharma |
Report Scope | Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Demand and Supply Side Analysis; Competitive Landscape; Company Profiling |
Segments Covered | By Test Type, By Application, By End User, By Region/Country |
Reasons to buy this report:
The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
The report presents a quick review of overall industry performance at one glance.
The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
The study comprehensively covers the market across different segments.
Deep dive regional level analysis of the industry.
Customization Options:
The global Latent TB Testing market can be customized further as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
Table of Contents
Research Methodology for the Latent TB Testing Market Analysis (2022-2032)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global Latent TB Testing market were the three major steps undertaken to create and analyze the adoption of Latent TB Testing in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global Latent TB Testing market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
A detailed secondary study was conducted to obtain the historical market size of the Latent TB Testing market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the Latent TB Testing market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as test type, application, end user, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the Latent TB Testing market. Further, we conducted factor analysis using dependent and independent variables such as test type, application, end user, and regions of the Latent TB Testing market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the Latent TB Testing market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global Latent TB Testing market, and market shares of the segments. All the required percentage shares split and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2032 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
The industry’s market size, in terms of revenue (USD) and the adoption rate of the Latent TB Testing market across the major markets domestically
All percentage shares, splits, and breakdowns of market segments and sub-segments
Key players in the global Latent TB Testing market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global Latent TB Testing market. Data was split into several segments and sub-segments after studying various parameters and trends in the test type, application, end user, and regions of the global Latent TB Testing market.
The main objective of the Global Latent TB Testing Market Study
The current & future market trends of the global Latent TB Testing market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Analyze the current and forecast market size of the Latent TB Testing market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments.
Segments in the study include areas of test type, application, end user, and regions.
Define and analyze the regulatory framework for the Latent TB Testing
Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
Analyze the current and forecast market size of the Latent TB Testing market for the major region.
Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World
Company profiles of the Latent TB Testing market and the growth strategies adopted by the market players to sustain the fast-growing market.
Deep dive regional level analysis of the industry.
Frequently Asked Questions FAQs
Q1: What is the Latent TB Testing market's current size and growth potential?
The Latent TB Testing market was valued at USD 1.4 Billion in 2023 and is expected to grow at a CAGR of 7.8% during the forecast period (2024-2032).
Q2: What are the driving factors for the growth of the Latent TB Testing market?
The rising tuberculosis (TB) incidence, increased need for screening in HIV/AIDS and transplant patients, rising advanced diagnostics, and adoption of IGRAs drive the Latent TB Testing market.
Q3: Which segment has the largest share of the Latent TB Testing market by test type?
Tuberculin Skin Test (TST) has the largest share of the Latent TB Testing market by test type.
Q4: What are the major trends in the Latent TB Testing market?
The integration of digital healthcare, and expansion of private diagnostics in emerging economies is the major trend in the Latent TB Testing market.
Q5: Which region will dominate the Latent TB Testing market?
North America dominated the market in 2023.
Related Reports
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
